Drug Retail

JD HEALTH

JD Health and AliHealth stocks fall on GLP-1 regulatory concerns, brokers call overreaction

JD Health spends 8.9453 million HKD to repurchase 198,100 shares on May 15

CSC Financial Maintains Buy Rating on JD Health International with Target Price of 58.28 HKD

Nomura lowers JD Health target price to HKD 67, maintains Buy rating

JD Health Authorized to Repurchase Up to $1 Billion in Shares

JD Health Reports Q1 2026 Revenue Growth of 17.0% to 19.468 Billion Yuan

JD Health Sees Significant Increase in New Drug Premieres in 2025

JD Health and China Resources Sanjiu Collaborate to Extend TCM Services to Grassroots

JD Health Emphasizes AI-Driven Medical Services Expansion in 2025 Annual Report

JD Health Showcases Full Stack AI Progress in Pharmaceutical Services

JD Health Launches Upgraded JD Zhiyi to Enhance Doctor's Work Efficiency

JD Quick Delivery Pharmacy Launches Comprehensive New Merchant Lifecycle Support Program

JD Health Launches 100 Self-Operated Pharmacies in Jinan to Address Supply Shortfall

JD Bao Joins Forces with JD Health to Launch 'Yao Shengbao·Shouyibao' Insurance Benefit Product

JD Health Partners with Bangbang Vehicle to Launch Smart Electric Wheelchair

JD Health Announces Strong Revenue and Profit Growth in 2025 Earnings Report

JD Health Hosts Tasting Event To Showcase Health Industry Layout

Changfeng Pharmaceutical Signs Strategic Cooperation Agreement with JD Health in Respiratory and Nasal Field

JD Health Achieves Record High Net Profit Margin in 2025

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

09618

02618

06618

JD.com will launch its AI-integrated 618 Grand Promotion on May 30 at 8 p.m., offering discounts of up to 50% across various product categories. This marks the company's first promotion fully utilizing AI in its consumer-facing features and operations.

- JD.com will launch its 618 Grand Promotion at 8 p.m. on May 30, 2026.  
- The event will fully integrate AI across consumer-facing features and operations, offering discounts of up to 50% on various products.  
- This promotion marks a significant step for JD.com in enhancing its sales strategy through technology.

PUBT

JD-SW

JD.com

JD LOGISTICS

KraneShares 2x Long JD Daily ETF

JD-SWR

JD.com kicks off AI-integrated 618 Grand Promotion with discounts up to 50%

EBIZ

IBUY

ONLN

JD's 618 campaign will officially start at 8pm on May 30 and run until June 21. Eric Qi, Head of Platform Operations, announced continuous auction events during the preheating period, including the world's first simulation robot auction on May 22.

- The press conference for the JD 618 launch in 2026 announced that the campaign starts at 8 PM on May 30 and runs until June 21.  
- Eric Qi of JD-SW highlighted that there will be continuous auction events leading up to the launch, including the world's first simulation robot auction this Friday.  
- As of May 18, JD-SW's short selling was reported at $153.34 million with a ratio of 29.833%.

AASTOCKS News

SPDR S&P Retail ETF

Global X E-commerce ETF

Amplify Online Retail ETF

VanEck Retail ETF

ProShares Online Retail

JD 618 Campaign to Kick Off at 8pm on May 30

00241

512010

159929

510660

JD HEALTH and ALI HEALTH shares fell 3%-5% following concerns over new GLP-1 drug sales regulations in Shanghai. CLSA noted that online sales remain unaffected and the impact of potential restrictions would be manageable, as GLP-1 drugs constitute a low percentage of sales. Nomura echoed this sentiment, stating market reactions were overblown and maintaining a Buy rating on JD HEALTH with a target price of HKD67.

- JD HEALTH and ALI HEALTH experienced stock declines due to market concerns over new regulations requiring paper prescriptions for GLP-1 drugs in Shanghai.  
- Despite these concerns, current regulations still permit online sales of diabetes drugs, and both companies reported no operational changes or regulatory instructions.  
- Analysts believe that even if restrictions expand, the financial impact will be manageable, as GLP-1 drug sales represent a low single-digit percentage of overall sales for both firms.

ALI HEALTH

E Fund CSI 300 Health Care ETF

China Universal 800 Health Care ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Nomura Holdings, Inc.

Nomura

JD HEALTH-R

ALI HEALTH  and JD HEALTH Drop 3%-5% as CLSA Says Impact from GLP-1 Online Sales Restrictions Limited; Nomura: Market Overreacted

JD HEALTH-2.140 (-4.739%) Short selling $160.42M; Ratio 21.399% repurchased 198,000 shares of the company on the Stock Exchange of Hong Kong last Friday (15th), at prices ranging from HKD45.06 to HKD45.3 per share, involving HKD8.945 million.This marked the company's first share repurchase since the ordinary resolution was passed (20 June 2025), accounting for 0.006% of its share capital.(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-15 16:25.)

- JD HEALTH (06618.HK) repurchased 198,000 shares on May 15, 2026, at prices between HKD 45.06 and HKD 45.3 each, totaling HKD 8.945 million.  
- This was the company's first share repurchase since the ordinary resolution was passed on June 20, 2025, representing 0.006% of its share capital.  
- The stock experienced a decrease of 4.739%, with short selling reported at $160.42 million and a ratio of 21.399%.

JD HEALTH Repurchases 198,000 Shares Last Fri, Involving HKD8.945M

CICC analyst maintained a Buy rating on JD Health International, Inc. yesterday and set a price target of HK$66.20.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on JD Health International, Inc. is a Strong Buy with an average price target of HK$72.11.

- CICC analyst maintained a Buy rating on JD Health International, Inc. and set a price target of HK$66.20.  
- The analyst consensus on JD Health is a Strong Buy with an average price target of HK$72.11.  
- This indicates positive outlook and confidence in the company's performance among analysts.

Tip Ranks

CICC

JD Health International, Inc. (6618) Receives a Buy from CICC

In a report released yesterday, from CSC Financial maintained a Buy rating on JD Health International, Inc., with a price target of HK$58.28.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks The word on The Street in general, suggests a Strong Buy analyst consensus rating for JD Health International, Inc. with a HK$73.11 average price target.

- CSC Financial reaffirmed a Buy rating on JD Health International, Inc., setting a price target of HK$58.28.  
- The broader analyst consensus indicates a Strong Buy rating for JD Health International, Inc., with an average price target of HK$73.11.  
- This report highlights favorable expectations and confidence in the company's market performance.

CSC Financial Keeps Their Buy Rating on JD Health International, Inc. (6618)

DBS analyst Ben Wong has reaffirmed a Buy rating on JD with a price target of $36.00, while shares closed at $33.77. Wong, a 4-star analyst, has an average return of 11.3% and a 63.27% success rate. Additionally, Bank of America Securities also issued a Buy rating for JD, while Susquehanna maintained a Hold rating.

- DBS analyst Ben Wong reiterated a Buy rating on JD with a price target of $36.00, while shares closed at $33.77.  
- Wong holds a 4-star ranking on TipRanks, showcasing an average return of 11.3% and a success rate of 63.27%, and he covers stocks in the Real Estate sector.  
- Bank of America Securities also issued a Buy rating on JD, whereas Susquehanna maintained a Hold rating on the same day.

BEKE-W

LONGFOR GROUP

CHINA RES LAND

Bank of America

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

DBS Reaffirms Their Buy Rating on JD (JD)

Nomura has raised its target price for JD.com, Inc. to USD41 while maintaining a Buy rating. The company's 1Q results exceeded expectations, with a 4.9% YoY revenue increase and a 16% YoY rise in operating profit. Despite anticipated revenue declines in Q2 due to various factors, Nomura has improved its profit forecasts for 2026 and 2027 by 15% and 5%, respectively, citing enhanced profitability in JD Retail.

- Nomura's report highlights that JD-SW (09618.HK) exceeded 1Q expectations with a 4.9% year-over-year increase in net revenue.  
- JD Retail's operating profit rose 16% year-over-year to RMB 15 billion, but management anticipates a decline in revenue for the second quarter due to various factors.  
- Despite this, Nomura improved its non-GAAP profit forecasts for 2026 and 2027 and maintained a Buy rating on JD.com, raising the target price from USD 40 to USD 41.

Nomura Raises JD.com, Inc.  TP to USD41, Maintains Buy Rating

Nomura has lowered its target price for JD HEALTH from HKD80 to HKD67, citing a decline in non-operating income that impacted net profit. Despite a 17% YoY revenue growth and a 48% increase in non-IFRS operating profit, non-IFRS net profit rose only 6% YoY due to fair value losses. Nomura maintains a Buy rating, viewing the current share price as attractive at 12x 2026E adjusted P/E.

- JD HEALTH reported a 17% year-on-year revenue growth in Q1, meeting broker Nomura's expectations.  
- The company's non-IFRS operating profit increased by 48% to RMB 1.9 billion, supported by gross margin expansion and higher advertising revenue, although non-operating income fell due to fair value losses from wealth management products.  
- Nomura maintains a Buy rating, adjusting the target price from HKD 80 to HKD 67, citing an attractive 12x 2026E adjusted P/E ratio.

Nomura Drops JD HEALTH  TP to HKD67; 1Q Non-operating Income Decline Dents Net Profit

JD HEALTH(06618.HK)

JD.com kicks off AI-integrated 618 Grand Promotion with discounts up to 50%

JD 618 Campaign to Kick Off at 8pm on May 30

ALI HEALTH and JD HEALTH Drop 3%-5% as CLSA Says Impact from GLP-1 Online Sales Restrictions Limited; Nomura: Market Overreacted

JD HEALTH Repurchases 198,000 Shares Last Fri, Involving HKD8.945M

JD Health International, Inc. (6618) Receives a Buy from CICC

CSC Financial Keeps Their Buy Rating on JD Health International, Inc. (6618)

DBS Reaffirms Their Buy Rating on JD (JD)

Nomura Raises JD.com, Inc. TP to USD41, Maintains Buy Rating

Nomura Drops JD HEALTH TP to HKD67; 1Q Non-operating Income Decline Dents Net Profit